Mostrando 4 resultados de: 4
Filtros aplicados
Subtipo de publicación
Article(4)
Publisher
Therapeutic Drug Monitoring(2)
European Journal of Clinical Pharmacology(1)
Journal of Psychopharmacology(1)
Área de conocimiento
Farmacología(4)
Origen
scopus(4)
Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes
ArticleAbstract: Sixteen hospitalized white European Spanish psychiatric patients treated with thioridazine alone werPalabras claves:CYP2D6, debrisoquine, Inhibition, ThioridazineAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P., Fernández-Salguero P.Fuentes:scopusUse of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity
ArticleAbstract: Thioridazine is metabolized in humans by CYP2D6 to mesoridazine, which is an active metabolite. TwoPalabras claves:CYP2D6, High-pressure liquid chromatography, pharmacogenetics, Therapeutic drug monitoring (TDM), ThioridazineAutores:Adrián LLerena, Benitez Rodriguez J., Berecz R., De la Rubia A., Norberto M.Fuentes:scopusQTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients
ArticleAbstract: Thioridazine cardiotoxicity has been associated with a prolonged heart-rate corrected QT (QTc) interPalabras claves:CYP2D6, debrisoquine, QTc lengthening, ThioridazineAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P.Fuentes:scopusThioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype
ArticleAbstract: Background: Approximately 7% of Caucasians have genetically impaired activity of the cytochrome P450Palabras claves:Cytochrome p450, pharmacogenetics, smoking, ThioridazineAutores:Adrián LLerena, Berecz R., Dahl M.L., De la Rubia A., Dorado P., Fernández-Salguero P.Fuentes:scopus